样式: 排序: IF: - GO 导出 标记为已读
-
Is Economic Evaluation and Care Commissioning Focused on Achieving the Same Outcomes? Resource-Allocation Considerations and Challenges Using England as a Case Study Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-03-11 Matthew Franklin, Sebastian Hinde, Rachael Maree Hunter, Gerry Richardson, William Whittaker
Commissioning describes the process of contracting appropriate care services to address pre-identified needs through pre-agreed payment structures. Outcomes-based commissioning (i.e., paying services for pre-agreed outcomes) shares a common goal with economic evaluation: achieving value for money for relevant outcomes (e.g., health) achieved from a finite budget. We describe considerations and challenges
-
Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-03-07 Jyoti Dixit, Pankaj Malhotra, Nikita Mehra, Anisha Mathew, Lalit Kumar, Ashish Singh, Nidhi Gupta, Manjunath Nookala Krishnamurthy, Partha Sarathi Roy, Amal Chandra Kataki, Sudeep Gupta, Shankar Prinja
-
#SharingHEOR: Developing Modern Media for Communication and Dissemination of Health Economics and Outcomes Research Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-03-01 Davene R. Wright, Mikaela Batista, Tim Wrightson
-
Cost of Low-Value Imaging Worldwide: A Systematic Review Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-03-01 Elin Kjelle, Ingrid Øfsti Brandsæter, Eivind Richter Andersen, Bjørn Morten Hofmann
-
The Impact of Raising Alcohol Taxes on Government Tax Revenue: Insights from Five European Countries Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-02-22 Jakob Manthey, Inese Gobiņa, Laura Isajeva, Jarosław Neneman, Rainer Reile, Mindaugas Štelemėkas, Jürgen Rehm
-
Simplified Methods for Modelling Dependent Parameters in Health Economic Evaluations: A Tutorial Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-02-20
Abstract Background In health economic evaluations, model parameters are often dependent on other model parameters. Although methods exist to simulate multivariate normal (MVN) distribution data and estimate transition probabilities in Markov models while considering competing risks, they are technically challenging for health economic modellers to implement. This tutorial introduces easily implementable
-
Rationing in an Era of Multiple Tight Constraints: Is Cost-Utility Analysis Still Fit for Purpose? Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-02-08 Helen Dakin, Apostolos Tsiachristas
Cost-utility analysis may not be sufficient to support reimbursement decisions when the assessed health intervention requires a large proportion of the healthcare budget or when the monetary healthcare budget is not the only resource constraint. Such cases include joint replacement, coronavirus disease 2019 (COVID-19) interventions and settings where all resources are constrained (e.g. post-COVID-19
-
Evidence Synthesis and Linkage for Modelling the Cost-Effectiveness of Diagnostic Tests: Preliminary Good Practice Recommendations Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-02-05 Bethany Shinkins, A. Joy Allen, James Karichu, Louis P. Garrison, Brigitta U. Monz
-
What Interventions are Cost Effective in Reducing Violence Against Women? A Scoping Review Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-01-27 Lauren Sheppard, Moosa Alsubhi, Vicki Brown, Ha Le, Kim Robinson, Marj Moodie
-
Health Interventions May Have Divergent Impacts on Health and Economic Equity: A Case Study of the Community-Based Hypertension Improvement Project in Ghana Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-01-24
Abstract Background and Objective Improving health and economic equity are key objectives in priority setting, particularly in low-income and middle-income countries. This study aims to assess the distributional impacts of the Community-based Hypertension Improvement Project (ComHIP) on health and economic outcomes across wealth quintiles in Ghana. Methods We developed a decision analytical model to
-
Comparing Preferences for Disease Profiles: A Discrete Choice Experiment from a US Societal Perspective Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-01-23 Karissa M. Johnston, Ivana F. Audhya, Jessica Dunne, David Feeny, Peter Neumann, Daniel C. Malone, Shelagh M. Szabo, Katherine L. Gooch
-
Estimating Transition Probabilities for Modeling Major Depression in Adolescents by Sex and Race or Ethnicity Combinations in the USA Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-01-22 Tran T. Doan, David W. Hutton, Davene R. Wright, Lisa A. Prosser
-
Are Web-Based Valuation Surveys for Preference-Based Measures as Reliable as Face-to-Face Surveys? TTO, DCE and DCE with Duration Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-01-13
Abstract Background Valuation surveys of preference-based measures are typically conducted face-to-face or on web panels. In this survey, we considered whether face-to-face and online surveys were reliable using three tasks: composite time trade-off (cTTO), discrete choice experiment (DCE), and DCE with duration. Methods Respondents (aged 20–69 years) for both face-to-face (N = 1000, target sample
-
A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-01-12 Néboa Zozaya, Javier Villaseca, Irene Fernández, Fernando Abdalla, Benito Cadenas-Noreña, Miguel Ángel Calleja, Pedro Gómez-Pajuelo, Jorge Mestre-Ferrándiz, Juan Oliva-Moreno, José Luis Trillo, Álvaro Hidalgo-Vega
Objectives The aim of this study was to review the current evaluation and funding processes for new drugs in different developed countries, to provide a comparative framework with detailed, homogeneous, and up-to-date information. Methods Scientific publications, reports and websites were reviewed between July and December 2021 using PubMed, Google Scholar, and grey literature sources. The main items
-
Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-01-10 Nidhi Gupta, Dharna Gupta, Kiran Gopal Vaska, Shankar Prinja
-
Do Informal Care Recipients Internalise Carer Burden? Examining the Impact of Informal Care Receipt on Health Behaviours Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-01-10 Jack Elliott, Igor Francetic, Rachel Meacock, Matt Sutton
-
The Limitations and Potentials of Evaluating Economic Aspects of Community-Based Health Promotion: A Critical Review Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2024-01-08
Abstract Community-based health promotion (CBHP) interventions are promising approaches to address public health problems; however, their economic evaluation presents unique challenges. This review aims to explore the opportunities and limitations of evaluating economic aspects of CBHP, focusing on the assessment of intervention costs and outcomes, and the consideration of political-level changes and
-
An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-12-22 Aidan Hollis
Conflicts over pharmaceutical pricing are driven by the patients’ need for affordable medicines and the producer’s reward for the investments in developing innovative medicines. A single price cannot achieve both goals, as it will either obstruct access by patients or provide too low a return to investors. This has led to calls to “delink” the payment for innovation from the price paid for drugs, so
-
Treatment Preferences of Adolescents and Young Adults with Depressive Symptoms: A Discrete Choice Experiment Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-12-18 Ruth C. Waumans, Anna D. T. Muntingh, Jorien Veldwijk, Adriaan W. Hoogendoorn, Anton J. L. M. van Balkom, Neeltje M. Batelaan
-
Participatory Value Evaluation (PVE): A New Preference-Elicitation Method for Decision Making in Healthcare Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-12-16
Abstract Participatory value evaluation (PVE) has recently been introduced in the field of health as a new method to elicit stated preferences for public policies. PVE is a method in which respondents in a choice experiment are presented with various policy options and their attributes, and are asked to compose their portfolio of preference given a public-resource constraint. This paper aims to illustrate
-
Should Commercial Diagnostic Testing Be Stimulated or Discouraged? Analyzing Willingness-to-Pay and Market Externalities of Three Commercial Diagnostic Tests in The Netherlands Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-12-15 Niek Stadhouders, Ella van Vliet, Anne E.M. Brabers, Wieteke van Dijk, Suzanne Onstwedder
-
Cost Effectiveness of Deep Brain Stimulation for Parkinson’s Disease: A Systematic Review Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-11-28 Akhil Sasidharan, Bhavani Shankara Bagepally, S Sajith Kumar
-
Adding a Gene Expression Profile Test to Aid Differential Diagnosis and Treatment in Aggressive Large B-Cell Lymphoma: An Early Exploratory Economic Evaluation Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-11-28 Janet Bouttell, Heather Fraser, John R. Goodlad, David Hopkins, Pam McKay, Karin A. Oien, Bruce Seligmann, Stephan von Delft, Neil Hawkins
-
Health Service Utilisation of People Living with Psychosis: Validity of Self-report Compared with Administrative Data in a Randomised Controlled Trial Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-11-21 Vergil Dolar, Mary Lou Chatterton, Long Khanh-Dao Le, Cathrine Mihalopoulos, Neil Thomas, Lidia Engel
-
Local Level Economic Evaluation: What is it? What is its value? Is it Sustainable? Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-11-18 Jonathan Karnon, Andrew Partington, Jodi Gray, Aubyn Pincombe, Timothy Schultz
-
Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-11-15 Shoroq M. Altawalbeh, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith
-
Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United Kingdom Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-11-10 Max Kindred, Zahratu Shabrina, Neily Zakiyah
-
Use of Health Technology Assessment for the Continued Funding of Health Technologies: The Case of Immunoglobulins for the Management of Multifocal Motor Neuropathy Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-11-11 Constanza Vargas, Rebecca Addo, Milena Lewandowska, Philip Haywood, Richard De Abreu Lourenco, Stephen Goodall
-
Modelling Informal Carers’ Health-Related Quality of Life: Challenges for Economic Evaluation Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-11-10 Becky Pennington, Hareth Al-Janabi
There has been increasing interest in including carers’ health-related qualify of life (HRQoL) in decision models, but currently there is no best practice guidance as to how to do so. Models thus far have typically assumed that carers’ HRQoL can be predicted from patient health states, as we illustrate with three examples of disease-modifying treatments. However, this approach limits the mechanisms
-
Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-11-01 Rui Li, Pengyi Lu, Christopher K. Fairley, José A. Pagán, Wenyi Hu, Qianqian Yang, Guihua Zhuang, Mingwang Shen, Yan Li, Lei Zhang
-
Methods for Economic Evaluations of Novel Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-10-29 Yan Li, Pingyu Chen, Xintian Wang, Qian Peng, Shixia Xu, Aixia Ma, Hongchao Li
-
Adding Value to CHEERS: New Reporting Standards for Value of Information Analyses. Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-10-25 Jonathan Karnon,Clarabelle Pham
-
Challenges in the Evaluation of Emerging Highly Specialised Technologies: Is There a Role for Living HTA? Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-10-12 Tracy Merlin, Jackie Street, Drew Carter, Hossein Haji Ali Afzali
-
Different Frameworks, Similar Results? Head-to-Head Comparison of the Generic Preference-Based Health-Outcome Measures CS-Base and EQ-5D-5L Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-10-12 Xin Zhang, Karin M. Vermeulen, Paul F. M. Krabbe
-
A Systematic Review of the World’s Largest Government Sponsored Health Insurance Scheme for 500 Million Beneficiaries in India: Pradhan Mantri Jan Arogya Yojana Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-10-06 Aashima, Rajesh Sharma
-
The Inflation Reduction Act: Hope for Prescription Drug Prices in the USA. Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-10-06 Lindsay Allen
-
Psychometric Evaluation of the PedsQL GCS and CHU9D in Australian Children and Adolescents with Common Chronic Health Conditions Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-10-03 Rakhee Raghunandan, Kirsten Howard, Sarah Smith, Anagha Killedar, Erin Cvejic, Martin Howell, Stavros Petrou, Emily Lancsar, Germaine Wong, Jonathan Craig, Alison Hayes
-
VOLY: The Monetary Value of a Life-Year at the End of Patients’ Lives Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-10-04 Elizabeta Ribarić, Ismar Velić, Ana Bobinac
-
Evaluating the Short-Term Costs and Benefits of a Nationwide Diabetes Prevention Programme in England: Retrospective Observational Study Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-10-03 Emma McManus, Rachel Meacock, Beth Parkinson, Matt Sutton
Background Prevention programmes typically incur short-term costs and uncertain long-term benefits. We use the National Health Service (NHS) England Diabetes Prevention Programme (NHS-DPP) to investigate whether behaviour change programmes may be cost-effective even within the short-term participation period. Methods We analysed 384,611 referrals between June 2016 and March 2019. We estimated NHS costs
-
Child–Parent Agreement in the Assessment of Health-Related Quality of Life Using the CHU9D and the PedsQLTM Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-09-29 Diana Khanna, Jyoti Khadka, Christine Mpundu-Kaambwa, Julie Ratcliffe
-
Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-09-26 Aniek Dane, Anne-Sophie Klein Gebbink, Jan-Dietert Brugma, Albane Degrassat-Théas, Martin J. Hug, Morten B. Houlind, P. Paubel, P. Hugo M. van der Kuy, Carin A. Uyl-de Groot
-
Economic Evaluations of Imaging Biomarker-Driven Companion Diagnostics for Cancer: A Systematic Review Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-09-25 Sibo Liu, Daniel SW Tan, Nicholas Graves, Ann-Marie Chacko
-
The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022 Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-09-02 Michela Meregaglia, Francesco Malandrini, Stefania Angelini, Oriana Ciani
-
Is Using Sodium-Glucose Cotransporter-2 Inhibitors to Treat Adults with Chronic Heart Failure Cost-Effective? A Systematic Review of Cost-Effectiveness Studies Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-08-30 Yi Jing Tan, Siew Chin Ong, Ying Min Kan
-
Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-08-22 Martin Vu, Koen Degeling, Ella R. Thompson, Piers Blombery, David Westerman, Maarten J. IJzerman
-
Projected Impact on Labour Productivity Costs of Cancer-Related Premature Mortality in Europe 2018–2040 Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-08-08 Marta Ortega-Ortega, Paul Hanly, Alison Pearce, Isabelle Soerjomataram, Linda Sharp
Aim To estimate the potential cost of lost labour productivity due to cancer-related premature mortality in Europe (EU-27 plus Norway, Switzerland, Iceland and United Kingdom) from 2018 to 2040. Methods Deaths and years of potential productive life lost due to 23 types of cancer were estimated for 2018–2040, for 31 European countries. The data were analysed by age groups, by sex and by year. Projected
-
The Economic Cost of Rising Non-communicable Diseases in India: A Systematic Literature Review of Methods and Estimates Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-07-28 Varsha Shukla, Rahul Arora
-
Health Reform in Aotearoa New Zealand: Insights on Health Equity Challenges One Year On Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-07-20 Paula K. Lorgelly, Daniel J. Exeter
-
Values in Modelling: Video Series Development and Evaluation Survey. Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-07-05 Stephanie Harvard,Adam Easterbrook,Greg Werker,Alison McLean,Amin Adibi,David Murphy
-
Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-07-03 Karel H. van der Pol, Mohamad Aljofan, Olivier Blin, Jan H. Cornel, Gerard A. Rongen, Aurélie-Gaëlle Woestelandt, Michael Spedding
Drug repurposing is the process of identifying a new use for an existing drug or active substance in an indication outside the scope of the original indication. Drug repurposing has important advantages including reduced development time and costs, and potentially large societal healthcare cost savings. However, current generic drug repurposing research faces a number of challenges in obtaining research
-
Cost-Effectiveness of Anti-retroviral Adherence Interventions for People Living with HIV: A Systematic Review of Decision Analytical Models Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-06-30 Ali Ahmed, Juman Abdulelah Dujaili, Lay Hong Chuah, Furqan Khurshid Hashmi, Long Khanh-Dao Le, Saval Khanal, Ahmed Awaisu, Nathorn Chaiyakunapruk
-
A Systematic Review of Cost-Effectiveness Analyses of Colorectal Cancer Screening in Europe: Have Studies Included Optimal Screening Intensities? Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-06-28 Rajani Pokharel, Yi-Shu Lin, Ethna McFerran, James F. O’Mahony
-
Direct Medical Costs of COPD in the USA: An Analysis of the Medical Expenditure Panel Survey 2017–2018 Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-06-03 Chintal H. Shah, Robert M. Reed, Linda Wastila, Eberechukwu Onukwugha, Mathangi Gopalakrishnan, Zafar Zafari
-
What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-05-30 Marion Tano, Pascal Paubel, Matthieu Ribault, Albane Degrassat-Théas
-
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany? Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-05-30 Melanie Büssgen, Tom Stargardt
-
myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-05-28 Heather Davies, Mary Chappell, Yingying Wang, Angaja Phalguni, Stephanie Wake, Mick Arber, Judith Shore
myCOPD is a digital tool designed for people to manage their chronic obstructive pulmonary disease (COPD). It requires a device with an internet connection and incorporates tools for education, self-management, symptom tracking and pulmonary rehabilitation (PR). myCOPD was selected for medical technologies guidance by the UK National Institute for Health and Care Excellence (NICE) in 2020. The External
-
Symptomatic SARS-CoV-2 Episodes and Health-Related Quality of Life Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-05-27 Caterina Alacevich, Inna Thalmann, Catia Nicodemo, Simon de Lusignan, Stavros Petrou
-
Modelled Distributional Cost-Effectiveness Analysis of Childhood Obesity Interventions: A Demonstration Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-05-23 Anagha Killedar, Thomas Lung, Rachael W. Taylor, Alison Hayes
-
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-05-12 Jaesh Naik, Norma Beavers, Fredrik O. L. Nilsson, Laura Iadeluca, Chrissy Lowry
-
Public Preferences for Introducing a COVID-19 Certificate: A Discrete Choice Experiment in the Netherlands Appl. Health Econ. Health Policy (IF 3.6) Pub Date : 2023-05-08 J. Veldwijk, J. van Exel, E. W. de Bekker-Grob, N. Mouter